Eco Quest today announced that its strategic partner, stem cell company Cynata Incorporated, has received positive results from a proof of concept study, indicating a potential role for mesenchymoangioblast (MCA)-based therapeutics in the treatment of Critical Limb Ischemia (CLI).
Cynata has exclusive access to investigate MCAs, discovered by company co-founder, Professor Igor Slukvin, and is in the process of negotiating an exclusive global licence.
CLI is a disease of poor blood supply (ischemia) to a limb, and is commonly found in diabetic patients. CLI patients suffer severe pain and skin ulcers, and up to 30% will have to undergo a lower limb amputation within a year of diagnosis. The principal goal of CLI management is the avoidance of amputation.
MCAs are critical precursors to the vascular system. Consequently, the company believes that therapeutics derived from these cells will have great utility in treating diseases such as CLI, where restoration of damaged vasculature is key.
For further information please download PDF below: